Abstract OT2-06-01: Phase I/II study of T-DM1 alone versus T-DM1 and metronomic temozolomide in secondary prevention of HER2-Positive breast cancer brain metastases following stereotactic radiosurgery

2018 ◽  
Author(s):  
AS Zimmer ◽  
B Gril ◽  
S Steinberg ◽  
D Smart ◽  
M Gilbert ◽  
...  
Keyword(s):  
Breast Cancer ◽  
Secondary Prevention ◽  
Brain Metastases ◽  
Phase I ◽  
Stereotactic Radiosurgery ◽  
Her2 Positive ◽  
Her2 Positive Breast Cancer ◽  
Breast Cancer Brain Metastases ◽  
Positive Breast Cancer

scholarly journals Temozolomide in secondary prevention of HER2-positive breast cancer brain metastases

2020 ◽  
Vol 16 (14) ◽  
pp. 899-909 ◽  
Author(s):  
Alexandra S Zimmer ◽  
Seth M Steinberg ◽  
Dee Dee Smart ◽  
Mark R Gilbert ◽  
Terri S Armstrong ◽  
...  
Keyword(s):  
Breast Cancer ◽  
Secondary Prevention ◽  
Brain Metastases ◽  
Local Treatment ◽  
Breast Cancer Patients ◽  
Her2 Positive ◽  
Her2 Positive Breast Cancer ◽  
Prevention Clinical Trial ◽  
Breast Cancer Brain Metastases ◽  
Positive Breast Cancer

Brain metastases occur in up to 25–55% of patients with metastatic HER2-positive breast cancer. Standard treatment has high rates of recurrence or progression, limiting survival and quality of life in most patients. Temozolomide (TMZ) is known to penetrate the blood–brain barrier and is US FDA approved for treatment of glioblastoma. Our group has demonstrated that low doses of TMZ administered in a prophylactic, metronomic fashion can significantly prevent development of brain metastases in murine models of breast cancer. Based on these findings, we initiated a secondary-prevention clinical trial with oral TMZ given to HER2-positive breast cancer patients with brain metastases after recent local treatment in combination with T-DM1 for systemic control of disease. Primary end point is freedom from new brain metastases at 1 year. (NCT03190967).

T-DM1 in HER2-positive breast cancer brain metastases (BM).

2014 ◽  
Vol 32 (15_suppl) ◽  
pp. 650-650 ◽  
Author(s):  
Rupert Bartsch ◽  
Anna Sophie Berghoff ◽  
Margareta Rudas ◽  
Elisabeth Bergen ◽  
Michael Gnant ◽  
...  
Keyword(s):  
Breast Cancer ◽  
Brain Metastases ◽  
Her2 Positive ◽  
Her2 Positive Breast Cancer ◽  
Breast Cancer Brain Metastases ◽  
Positive Breast Cancer

scholarly journals LCCC 1025: a phase II study of everolimus, trastuzumab, and vinorelbine to treat progressive HER2-positive breast cancer brain metastases

2018 ◽  
Vol 171 (3) ◽  
pp. 637-648 ◽  
Author(s):  
Amanda E. D. Van Swearingen ◽  
Marni B. Siegel ◽  
Allison M. Deal ◽  
Maria J. Sambade ◽  
Alan Hoyle ◽  
...  
Keyword(s):  
Breast Cancer ◽  
Brain Metastases ◽  
Phase Ii ◽  
Phase Ii Study ◽  
Her2 Positive ◽  
Her2 Positive Breast Cancer ◽  
Breast Cancer Brain Metastases ◽  
Positive Breast Cancer

Abstract P6-16-10: Activity of T-DM1 in HER2-positive breast cancer brain metastases

2015 ◽  
Author(s):  
Rupert Bartsch ◽  
Anna S Berghoff ◽  
Ursula Vogl ◽  
Margaretha Rudas ◽  
Elisabeth Bergen ◽  
...  
Keyword(s):  
Breast Cancer ◽  
Brain Metastases ◽  
Her2 Positive ◽  
Her2 Positive Breast Cancer ◽  
Breast Cancer Brain Metastases ◽  
Positive Breast Cancer
Sign in / Sign up

Export Citation Format

Share Document